Ubuvuzi bwa Seli za NS7CAR-T bwerekanye icyizere cyo kuvura R/R T-ALL/LBL

Isohoka riherutse mu kinyamakuru Blood ryibanze cyane ku bushobozi bw'ubuvuzi bwa selile za NS7CAR-T mu kuvura leukemia ya T-cell acute lymphoblastic leukemia (R/R T-ALL) yasubiwemo cyangwa idakira (R/R T-ALL) na lymphoma ya T-cell lymphoblastic (R/R T-LBL). Ubushakashatsi, bwakozwe nk'igerageza rya mbere ry'ubuvuzi (ClinicalTrials.gov: NCT04572308), bwasuzumye umutekano n'ubushobozi bw'ubu buryo bushya bwo kuvura.

Igerageza ryakozwemo abarwayi bafite R/R T-ALL/LBL bahawe selile za NS7CAR-T. Ibisubizo byagaragaje ko ubuvuzi bwa NS7CAR-T butari bufite umutekano gusa, ahubwo bwanagaragaje imikorere itangaje yo kurwanya ibibyimba. Abarwayi bavuwe selile za NS7CAR-T bagaragaje ibisubizo bikomeye ku buvuzi, bigaragaza ko ubu buryo bushobora kuba igikoresho gikomeye cyo kurwanya izi kanseri zikomeye.

Abashakashatsi bakoze ubushakashatsi barimo itsinda ry’inzobere zo mu bitaro bya Hebei Yanda Lu Daopei na Hebei Senlang Biotechnology Co., Ltd. Ibyo babonye bigaragaza ko uturemangingo twa NS7CAR-T dushobora gukorwa neza hatabayeho izindi mpinduka mu ngirabuzimafatizo kugira ngo hakumirwe ikwirakwizwa rya CD7, koroshya uburyo bwo kuyikora no kunoza imikorere y’ubuvuzi.

Iri terambere mu kuvura selile za NS7CAR-T rijyanye n'ingamba zikomeje gukorwa zo guteza imbere uburyo bwiza bwo kuvura T-ALL na T-LBL. Isosiyete yacu kandi irimo gutera imbere muri uru rwego hamwe n'isosiyete yacu yihariye. Igicuruzwa cya CAR-T, ibyo twizera ko bizahuza ibisubizo byiza byabonetse hamwe n’ubuvuzi bwa NS7CAR-T.

Ibisubizo bishimishije by’ubu bushakashatsi bitanga inzira y’ubushakashatsi n’igerageza ry’ubuvuzi kugira ngo hakorwe neza uruhare rw’uturemangingo twa NS7CAR-T mu kuvura kanseri ya T-cells yasubiwemo cyangwa itarakira. Uko amakuru menshi agenda aboneka, byifujwe ko ubu buryo bwo kuvura buzahinduka amahitamo asanzwe ku barwayi barwaye izi ndwara zikomeye.